MaaT Pharma Stock: Support at €2.98 Under Threat Before CHMP Vote in June
The stock of the Lyon-based biotech company plunges during the session, after a brief rebound on Friday. The stock is now trading at its lowest, as the formal vote of the European Medicines Committee approaches.
A New Session Low Further Breaches the Technical Support at €2.98
MaaT Pharma's stock fell 5.52% to €2.99 during the session, after dropping to €2.95 intraday. The stock briefly breached its support at €2.98, before just recovering above it. The weekly drop reaches 56.1%, a direct consequence of the shock experienced last Thursday after the CHMP's unfavorable signal on Xervyteg. The nearly 7% rebound observed on Friday did not hold. The technical configuration remains highly degraded. The price is trading 50% below its 20-day moving average (€6.04) and equally under its 50-day moving average (€6.08), while the 200-day moving average at €5.32 also drifts further away. The RSI at 23 indicates seller exhaustion for the week, without yet triggering a solid technical rebound. The support at €2.98 is now the only level preventing further decline.
Formal CHMP Vote in June and Revenue Announcement Expected Today
The central issue remains regulatory. The Committee for Medicinal Products for Human Use of the European Medicines Agency will deliver its formal vote in June on the conditional authorization request for Xervyteg (MaaT013), a treatment for acute graft-versus-host disease. The unfavorable trend communicated last week has already been largely factored in by the market, explaining the magnitude of the drop over seven days. Moreover, the financial calendar also schedules the publication of the first quarter 2026 revenue today. The biotech, based in Lyon, operates in an unfavorable macro context: the French composite PMI fell to 43.5 in May, its lowest since November 2020, weighing on the appetite for speculative stocks. The CAC 40 is down 0.94% at 8,180 points during the session. The next crucial appointment remains the CHMP vote in June, which will determine the European commercial horizon for the drug candidate.
